Beneficial Effects of Adjuvant Intravitreal Bevacizumab Injection on Outcomes of Ahmed Glaucoma Valve Implantation in Patients with Neovascular Glaucoma: Systematic Literature Review

Hwang, Hyung Bin; Han, Jeung-Sul; Yim, Hye Bin; Lee, Na Young

doi:10.1089/jop.2014.0108

Cited by 38 publications

(26 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another systematic review outside of Cochrane compared the Ahmed implant with intravitreal bevacizumab to the Ahmed implant alone for neovascular glaucoma (Hwang 2015). This review included both prospective and retrospective studies and a total of six studies with 256 eyes.…”

Section: Discussionmentioning

confidence: 99%

Aqueous shunts for glaucoma

Tseng¹,

Coleman²,

Chang³

2017

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Aqueous shunts for glaucoma

Tseng¹,

Coleman²,

Chang³

2017

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

“…We are planning a prospective investigator initiated trial in the future. Furthermore, we cannot try other now available superior anti-VEGF compounds [8] such as aflibercept [19] and devises like the tube surgical option of treatment [24–26] due to disapproval at that time. In addition, as LEC was performed after various treatments, including adequate PRP (100%), anti-VEGF stand-alone therapy (71.9%), and PPV (21.9%), it should be noted that extensive preparation is necessary for the success of LEC.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Factor Analysis of Intraocular Pressure with Neovascular Glaucoma

Nakano

Nakamuro

Yokoyama

et al. 2016

Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose. To perform multivariate analysis for identifying independent predictors of elevated intraocular pressure (IOP) with neovascular glaucoma (NVG), including antivascular endothelial growth factor (VEGF) intravitreal injections. Methods. We retrospectively reviewed 142 NVG patients (181 eyes) with ischemic retinal diseases [proliferative diabetic retinopathy (PDR) in 134 eyes, retinal vein occlusion (RVO) in 29, and ocular ischemic syndrome in 18]. We analyzed age, gender, initial/final LogMAR VA, initial/final IOP, extent of iris and/or angle neovascularization, treatments, preexisting complications, concurrent medications, and follow-up duration. Results. The mean follow-up duration was 23.8 ± 18.8 months. At the final follow-up, 125 (72.3%) eyes had IOP ≤ 21 mmHg. NVG patients with RVO had a higher degree of angle closure and higher IOP. NVG with PDR had better IOP and LogMAR VA. Angle closure had the greatest impact on final IOP. Greater than 90% of patients treated with trabeculectomy with mitomycin C (LEC) had persistent declines in IOP (≤21 mmHg). Stand-alone and combination anti-VEGF therapies were not associated with improved long-term prognosis of IOP. Conclusions. Angle closure was found to have the greatest effect on NVG-IOP prognosis. When target IOP values are not obtained after adequate PRP with or without anti-VEGF, early LEC may improve the prognosis of IOP.

show abstract

“…The role of IVB in NVG has been verified, 6,7 but some reports suggested only for short term. 8,9 IVB is part of the surgery to reduce short-term complications.…”

Section: -5mentioning

confidence: 99%

Combined Trabeculectomy with Mitomycinc, Pars Plana Vitrectomy with Panretinal Photocoagulation, and Intravitreal and Intracameral Bevacizumab for Neovascular Glaucoma

Lin¹,

Lee²

2016

Ophthalmol Open J

View full text Add to dashboard Cite

CitationLin H-Z, Lee Y-C. Combined trabeculectomy with mitomycinC, pars plana vitrectomy with panretinal photocoagulation, and intravitreal and intracameral bevacizumab for neovascular glaucoma. Otolaryngol Open J. The intraocular pressure returned to normal range soon after operation. The neovascularization of iris regressed in a few days. Mild hyphema developed in three patients. All six patients had improved or stable visual acuity, and achieved normal intraocular pressure without antiglaucoma medications three months after operation. Conclusions: This combined surgery may break the vicious cycle of neovascularglaucoma and preserve useful vision in these patients.

show abstract

Beneficial Effects of Adjuvant Intravitreal Bevacizumab Injection on Outcomes of Ahmed Glaucoma Valve Implantation in Patients with Neovascular Glaucoma: Systematic Literature Review

Abstract: AGV implantation with adjuvant bevacizumab was more effective and had a higher success rate than surgery alone for lowering IOP in patients with NVG. The combined procedure tended to show a lower incidence of bleeding-associated complications, such as hyphema.

Cited by 38 publications

References 23 publications

Aqueous shunts for glaucoma

Aqueous shunts for glaucoma

Prognostic Factor Analysis of Intraocular Pressure with Neovascular Glaucoma

Combined Trabeculectomy with Mitomycinc, Pars Plana Vitrectomy with Panretinal Photocoagulation, and Intravitreal and Intracameral Bevacizumab for Neovascular Glaucoma

Contact Info

Product

Resources

About